Ionis Pharmaceuticals Inc is a renowned biopharmaceutical company known for its commitment to scientific innovation and patient-centric solutions. The company's core values revolve around excellence, integrity, and collaboration. Ionis focuses on developing transformative RNA-targeted medicines to address a wide range of diseases with high unmet medical needs. With a strong corporate philosophy centered on rigorous scientific research, Ionis prioritizes the advancement of therapeutic solutions that improve patients' lives. Ionis Pharmaceuticals Inc's dedication to pioneering therapies and strategic partnerships underscores its mission to deliver novel treatments and drive positive healthcare outcomes.

Ionis Pharmaceuticals Inc is primarily present in the United States.

Ionis Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notably, the company pioneered the development of antisense technology, a groundbreaking approach to target and modulate the production of disease-causing proteins. Ionis has successfully advanced multiple antisense therapies into clinical trials and gained regulatory approvals for several of its drugs. Additionally, the company has established numerous collaborations with leading biopharmaceutical companies, further validating its innovative drug discovery platform. Ionis Pharmaceuticals Inc continues to make strides in the field of RNA-targeted therapeutics, aiming to improve the lives of patients affected by various diseases.

Ionis Pharmaceuticals Inc, formerly known as Isis Pharmaceuticals Inc, is a renowned biotechnology company headquartered in Carlsbad, California. Established in 1989, Ionis specializes in discovering and developing RNA-targeted therapeutics for various diseases. The company's innovative antisense technology allows the targeting of specific genes to treat a wide range of medical conditions. Ionis is recognized for its industry-leading pipeline of drugs, focusing on areas such as cardiovascular, metabolic, and neurological disorders. With a strong commitment to advancing healthcare through groundbreaking research and development, Ionis Pharmaceuticals Inc has emerged as a prominent player in the biotech sector, consistently striving to improve patients' lives.

The main competitors of Ionis Pharmaceuticals Inc in the market are Alnylam Pharmaceuticals, Biogen, and Moderna.

Ionis Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Ionis Pharmaceuticals Inc. focuses on developing RNA-targeted drugs to treat various diseases. By harnessing the power of antisense technology, Ionis utilizes genetic information to create specific RNA-targeted therapies that can selectively modulate gene expression, preventing or treating diseases at the molecular level. Ionis collaborates with pharmaceutical partners worldwide to advance its drug candidates through clinical development and commercialization. With its extensive pipeline and groundbreaking platform, Ionis aims to revolutionize the treatment of genetic diseases and offer hope to patients in need.

De Ionis Pharmaceuticals K/W is -12,23.

De Ionis Pharmaceuticals KUV is 11,41.

De AlleAktien Kwaliteitsscore voor Ionis Pharmaceuticals is 4/10.

De verwachte Ionis Pharmaceuticals omzet is 620,89 mln. USD.

De verwachte Ionis Pharmaceuticals winst is -579,11 mln. USD.

Ionis Pharmaceuticals Inc is a leading company in the field of RNA-based therapeutics. Since its founding in 1989, the company has been working to develop and bring to market innovative and effective therapies for numerous diseases. Today, the company employs over 800 people and is headquartered in Carlsbad, California. The business model of Ionis Pharmaceuticals is based on the development and commercialization of RNA-based therapeutics. These are drugs that are made based on ribonucleic acids (RNA). RNA is an important component of cells and is needed for the translation of genetic information into proteins. In the case of diseases, a disrupted RNA metabolism can lead to severe illnesses. Ionis Pharmaceuticals focuses on this aspect in the development of therapeutics and uses RNA to specifically intervene in disease mechanisms and correct them. The company has developed a broad portfolio of therapeutics. One of the most successful products is Spinraza, a medication for the treatment of spinal muscular atrophy (SMA), a hereditary disease of the motor nervous system. Spinraza is the first approved RNA-based therapeutic and has enabled a significant breakthrough in the development of this technology. Other products that the company has in its pipeline target the treatment of diseases such as diabetes, cancer, Alzheimer's, and other neurological disorders. The business model of Ionis Pharmaceuticals includes various divisions. In addition to the development of RNA-based therapeutics, the company also conducts research and development in the field of antisense technology. This involves the use of short nucleotide sequences to reduce protein expression. Unlike RNA therapy, antisense technology utilizes DNA. Ionis Pharmaceuticals is a pioneer in this field and has already developed numerous drugs based on this technology. Another important area for the company is the licensing and commercialization of therapeutics to partner companies. Ionis Pharmaceuticals has entered into a variety of collaborations with major pharmaceutical companies such as Roche, GlaxoSmithKline, and AstraZeneca. In these partnerships, the company is responsible for the development and clinical testing of the therapeutics, while the partners are responsible for the production, marketing, and distribution of the products. This allows Ionis Pharmaceuticals to leverage its expertise in RNA technology while benefiting from the distribution networks and experiences of its partner companies. Overall, the business model of Ionis Pharmaceuticals is positioned in a promising and rapidly growing market. The use of RNA and antisense technologies opens up completely new possibilities for the development of effective therapeutics for numerous diseases. With a broad portfolio of already approved and in-development drugs, as well as a strong partnership strategy, Ionis Pharmaceuticals is well-positioned to continue operating successfully in this field.

Ionis Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Ionis Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Ionis Pharmaceuticals is US4622221004.

Het WKN van Ionis Pharmaceuticals is A2ACMZ.

De ticker van Ionis Pharmaceuticals is IONS.

Binnen de laatste 12 maanden betaalde Ionis Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Ionis Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Ionis Pharmaceuticals is momenteel .

Ionis Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Ionis Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Ionis Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Ionis Pharmaceuticals van 1-8-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 1-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-8-2024.

In het jaar 2023 heeft Ionis Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Ionis Pharmaceuticals worden in USD uitgekeerd.